Oral sulfonylureas for the treatment of type II diabetes: an update.
Oral hypoglycemic agents have been in clinical use since 1956 in the United States. Two new second-generation sulfonylureas, glipizide and glyburide, have been marketed recently. This article reviews the pharmacology of the oral sulfonylureas, compares the drugs from a safety and efficacy standpoint, and provides updated information regarding their use in the management of type II non-insulin-dependent diabetes mellitus.
Shank
W A
WA
Morrison
A D
AD
D000284:Administration, Oral; D002747:Chlorpropamide / Q000009:adverse effects; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004342:Drug Hypersensitivity / Q000209:etiology; D005913:Glipizide / Q000008:administration & dosage / Q000378:metabolism / Q000627:therapeutic use; D005905:Glyburide / Q000008:administration & dosage / Q000378:metabolism / Q000627:therapeutic use; D006801:Humans; D007333:Insulin Resistance; D007700:Kinetics; D008099:Liver / Q000378:metabolism; D009325:Nausea / Q000139:chemically induced; D010353:Patient Education as Topic; D013453:Sulfonylurea Compounds / Q000008:administration & dosage / Q000378:metabolism / Q000627:therapeutic use*
D013453:Sulfonylurea Compounds; D005905:Glyburide; D002747:Chlorpropamide; D005913:Glipizide